Additionally, people with MS on immunomodulatory treatment (mostly consisting of IFN-b) were observed to have higher mean baseline levels of inflammation markers (IL-1Ra and CXCL16) compared to those not on therapy. The gene discussed is CXCL16; the disease is myeloid sarcoma.